Press release
September 14, 2026
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
MediWound Ltd. (MDWD)
Independent DSMB Recommends MediWound’s EscharEx ® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026